Susquehanna International Group
KNTE

Susquehanna International Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Susquehanna International Group’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-702,300
Closed -$1.87M – 13591
2024
Q1 		$1.87M Buy
702,300
+59,700
+9% +$148K ﹤0.01% 5498
2023
Q4 		$1.52M Buy
+642,600
New +$1.14M ﹤0.01% 5967
2023
Q2 		– Sell
-11,800
Closed -$73.8K – 13474
2023
Q1 		$73.8K Buy
+11,800
New +$71.9K ﹤0.01% 11502

Susquehanna International Group's KNTE Position: Q2 2024 in Review

Susquehanna International Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 526,021 shares — an estimated $1.4M sold.

Susquehanna International Group first reported a position in KNTE in Q4 2021 and held it in 7 quarters. The position peaked at $1.4M in Q1 2024. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

  • Susquehanna International Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Susquehanna International Group sold 526,021 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $1.4M.
  • Susquehanna International Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • Susquehanna International Group's Kinnate Biopharma Inc. Common Stock position peaked at $1.4M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.